---
title: "Candel Therapeutics, Inc. (CADL.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CADL.US.md"
symbol: "CADL.US"
name: "Candel Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T06:51:39.344Z"
locales:
  - [en](https://longbridge.com/en/quote/CADL.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CADL.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CADL.US.md)
---

# Candel Therapeutics, Inc. (CADL.US)

## Company Overview

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.candeltx.com](https://www.candeltx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -10.31 | 458 | - | - | - |
| PB | 4.07 | 299 | 4.69 | 3.91 | 3.29 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 8 | 89% |
| Hold | 1 | 11% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 7.66 |
| Highest Target | 29.00 |
| Lowest Target | 9.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CADL.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CADL.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CADL.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CADL.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**